Nanoparticle diffusion in spontaneously expectorated sputum as a biophysical tool to probe disease severity in COPD
暂无分享,去创建一个
V. Kim | N. Hansel | K. Carson | N. Putcha | R. Wise | J. S. Suk | J. Hanes | E. Neptune | J. Shade | S. Shenoy | Jane Chisholm
[1] E. Hoffman,et al. Airway Mucin Concentration as a Marker of Chronic Bronchitis , 2017, The New England journal of medicine.
[2] Benjamin C. Tang,et al. Nanoparticles that do not adhere to mucus provide uniform and long-lasting drug delivery to airways following inhalation , 2017, Science Advances.
[3] Gregg A. Duncan,et al. The Mucus Barrier to Inhaled Gene Therapy. , 2016, Molecular therapy : the journal of the American Society of Gene Therapy.
[4] Gregg A. Duncan,et al. Microstructural alterations of sputum in cystic fibrosis lung disease. , 2016, JCI insight.
[5] P. Gibson,et al. Neutrophil extracellular traps are associated with inflammation in chronic airway disease , 2016, Respirology.
[6] Laura M Ensign,et al. PEGylation as a strategy for improving nanoparticle-based drug and gene delivery. , 2016, Advanced drug delivery reviews.
[7] J. Wedzicha,et al. The Presence of Chronic Mucus Hypersecretion across Adult Life in Relation to Chronic Obstructive Pulmonary Disease Development. , 2016, American journal of respiratory and critical care medicine.
[8] Ajit Varki,et al. Acidic pH increases airway surface liquid viscosity in cystic fibrosis. , 2016, The Journal of clinical investigation.
[9] J. Wedzicha,et al. Impact of Prolonged Exacerbation Recovery in Chronic Obstructive Pulmonary Disease. , 2015, American journal of respiratory and critical care medicine.
[10] Benjamin S Schuster,et al. Particle tracking in drug and gene delivery research: State-of-the-art applications and methods. , 2015, Advanced drug delivery reviews.
[11] B. Qaqish,et al. The Relationship of Mucus Concentration (Hydration) to Mucus Osmotic Pressure and Transport in Chronic Bronchitis. , 2015, American journal of respiratory and critical care medicine.
[12] J. S. Suk,et al. Highly compacted biodegradable DNA nanoparticles capable of overcoming the mucus barrier for inhaled lung gene therapy , 2015, Proceedings of the National Academy of Sciences.
[13] M. Litt,et al. Mucus rheology and mucociliary clearance: Normal physiologic state. , 2015, The American review of respiratory disease.
[14] S. Hazen,et al. Oxidation increases mucin polymer cross-links to stiffen airway mucus gels , 2015, Science Translational Medicine.
[15] Ting-Yu Shih,et al. Brain-Penetrating Nanoparticles Improve Paclitaxel Efficacy in Malignant Glioma Following Local Administration , 2014, ACS nano.
[16] Scott A. McKinley,et al. A Biophysical Basis for Mucus Solids Concentration as a Candidate Biomarker for Airways Disease , 2014, PloS one.
[17] P. Abete,et al. A New Method to Improve the Clinical Evaluation of Cystic Fibrosis Patients by Mucus Viscoelastic Properties , 2014, PloS one.
[18] J. Hanes,et al. The microstructure and bulk rheology of human cervicovaginal mucus are remarkably resistant to changes in pH. , 2013, Biomacromolecules.
[19] M. Schlesser,et al. Chronic bronchitis in COPD patients is associated with increased risk of exacerbations: a cross‐sectional multicentre study , 2013, International journal of clinical practice.
[20] Bradley S. Turner,et al. The Influence of Mucus Microstructure and Rheology in Helicobacter pylori Infection , 2013, Front. Immunol..
[21] P. Kirkham,et al. Oxidative stress in COPD. , 2013, Chest.
[22] P. McDonnell,et al. Nanoparticle diffusion in, and microrheology of, the bovine vitreous ex vivo. , 2013, Journal of controlled release : official journal of the Controlled Release Society.
[23] G. Woodworth,et al. Nanoparticle diffusion in respiratory mucus from humans without lung disease. , 2013, Biomaterials.
[24] E. Arias,et al. Deaths: preliminary data for 2011. , 2012, National vital statistics reports : from the Centers for Disease Control and Prevention, National Center for Health Statistics, National Vital Statistics System.
[25] C. W. Davis,et al. CFTR, mucins, and mucus obstruction in cystic fibrosis. , 2012, Cold Spring Harbor perspectives in medicine.
[26] Elizabeth Nance,et al. A Dense Poly(Ethylene Glycol) Coating Improves Penetration of Large Polymeric Nanoparticles Within Brain Tissue , 2012, Science Translational Medicine.
[27] J. S. Suk,et al. Mucus Penetrating Nanoparticles: Biophysical Tool and Method of Drug and Gene Delivery , 2012, Advanced materials.
[28] A. Vestri,et al. Analysis of Sputum Markers in the Evaluation of Lung Inflammation and Functional Impairment in Symptomatic Smokers and COPD Patients , 2011, Disease markers.
[29] O. Mert,et al. Drug carrier nanoparticles that penetrate human chronic rhinosinusitis mucus. , 2011, Biomaterials.
[30] J. Hokanson,et al. The chronic bronchitic phenotype of COPD: an analysis of the COPDGene Study. , 2011, Chest.
[31] J. Fahy,et al. Airway mucus function and dysfunction. , 2010, The New England journal of medicine.
[32] J. Wedzicha,et al. Susceptibility to exacerbation in chronic obstructive pulmonary disease. , 2010, The New England journal of medicine.
[33] V. Brusasco,et al. Revisited role for mucus hypersecretion in the pathogenesis of COPD , 2010, European Respiratory Review.
[34] S. Young,et al. Macrorheology of cystic fibrosis, chronic obstructive pulmonary disease & normal sputum , 2009, Respiratory research.
[35] Michael P Boyle,et al. The penetration of fresh undiluted sputum expectorated by cystic fibrosis patients by non-adhesive polymer nanoparticles. , 2009, Biomaterials.
[36] Nicolas Roche,et al. Cough and sputum production are associated with frequent exacerbations and hospitalizations in COPD subjects. , 2009, Chest.
[37] Denis Wirtz,et al. Micro- and macrorheology of mucus. , 2009, Advanced drug delivery reviews.
[38] Kyubo Kim,et al. Mucus hypersecretion in asthma: causes and effects , 2009, Current opinion in pulmonary medicine.
[39] P. Paggiaro,et al. Biological Markers in Induced Sputum of Patients with Different Phenotypes of Chronic Airway Obstruction , 2008, Respiration.
[40] D. Rogers. Mucus hypersecretion in chronic obstructive pulmonary disease. , 2008, Novartis Foundation symposium.
[41] A L Hansell,et al. Proportional classifications of COPD phenotypes , 2008, Thorax.
[42] P. Paré,et al. Survival after lung volume reduction in chronic obstructive pulmonary disease: insights from small airway pathology. , 2007, American journal of respiratory and critical care medicine.
[43] Justin Hanes,et al. Rapid transport of large polymeric nanoparticles in fresh undiluted human mucus , 2007, Proceedings of the National Academy of Sciences.
[44] S. Ramsey,et al. Chronic obstructive pulmonary disease, risk factors, and outcome trials: comparisons with cardiovascular disease. , 2006, Proceedings of the American Thoracic Society.
[45] Scott H Randell,et al. Effective mucus clearance is essential for respiratory health. , 2006, American journal of respiratory cell and molecular biology.
[46] Amir Sharafkhaneh,et al. Airway mucus: From production to secretion. , 2006, American journal of respiratory cell and molecular biology.
[47] H. Danahay,et al. Epithelial mucus-hypersecretion and respiratory disease. , 2005, Current drug targets. Inflammation and allergy.
[48] S. Randell,et al. Reduced Three-Dimensional Motility in Dehydrated Airway Mucus Prevents Neutrophil Capture and Killing Bacteria on Airway Epithelial Surfaces1 , 2005, The Journal of Immunology.
[49] P. Janmey,et al. Elastic contributions dominate the viscoelastic properties of sputum from cystic fibrosis patients. , 2004, Biophysical chemistry.
[50] I. Adcock,et al. Mucin expression in peripheral airways of patients with chronic obstructive pulmonary disease , 2004, Histopathology.
[51] P. Paré,et al. The nature of small-airway obstruction in chronic obstructive pulmonary disease. , 2004, The New England journal of medicine.
[52] M. Knowles,et al. Mucus clearance as a primary innate defense mechanism for mammalian airways. , 2002, The Journal of clinical investigation.
[53] Denis Wirtz,et al. Particle Tracking Microrheology of Complex Fluids , 1997 .
[54] A Bast,et al. Oxidative stress in chronic obstructive pulmonary disease. Oxidative Stress Study Group. , 1997, American journal of respiratory and critical care medicine.
[55] J. Vestbo,et al. Association of chronic mucus hypersecretion with FEV1 decline and chronic obstructive pulmonary disease morbidity. Copenhagen City Heart Study Group. , 1996, American journal of respiratory and critical care medicine.
[56] Dl Hoyert,et al. National Vital Statistics Reports NCHS.pdf , 2012 .
[57] Q. Hamid,et al. Mucin overproduction in chronic inflammatory lung disease. , 2006, Canadian respiratory journal.
[58] L. Allegra,et al. Identification of subpopulations of bronchitic patients for suitable therapy by a dynamic rheological test. , 1989, International journal of clinical pharmacology research.